- ECOG E3A06- Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Mulitple Myeloma.
- SWOG S1211- Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamathasone, and Lenalidomide with/or without Elotuzumab for Newly Diagnosed High Risk Multiple Myeloma (HRMM).
- SWOG S1304- Randomized Phase II Study Comparing Two Doses of Carfilzomib with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.
- NCCTG N1087- Phase I/II Study of the Combination of Bendamustine, Rituximab and Akt Inhibitor MK2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
- SWOG S1117- Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).